Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

By Jennie Walters | Oct 16, 2018 | 5:31 AM GMT

Pharnext S.A. (Euronext:ALPHA) plans to submit regulatory applications to FDA and EMA in 2H19 for PXT3003 to treat mild to moderate Charcot-Marie-Tooth 1A (CMT1A) disease after

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE